View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 3, 2020

Teva’s Ajovy meets goals in Phase II/III trials in Japan

Teva Pharmaceutical has reported positive data from two Phase II/III clinical trials of Ajovy (fremanezumab) conducted to treat migraine patients in Japan.

Teva Pharmaceutical has reported positive data from two Phase II/III clinical trials of Ajovy (fremanezumab) conducted to treat migraine patients in Japan.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Ajovy is an anti-calcitonin gene-related peptide (CGRP) drug indicated in the US and EU for the preventive treatment of migraine.

In Japan, the drug is being developed by Otsuka Pharmaceutical, which signed an exclusive licence agreement in May 2017 for development and sales in the country.

Data from the Phase II/III trials in Japan showed that the primary goals were met, demonstrating clinical and statistical significance in patients with chronic migraine and episodic migraine, respectively, on Ajovy compared to placebo.

The drug also led to statistically significant improvements on all secondary endpoints. It was well-tolerated with an adverse events profile similar to that of placebo.

Results from these pivotal studies will enable the submission of an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) seeking marketing authorisation.

Teva Pharmaceutical Migraine & Headache global medical lead Joshua Cohen said: “This study adds to the wealth of positive AJOVY data we have in patients globally.

“The annual prevalence of migraine in Japan is 8.4% of adults, so we are pleased to be one step closer to bringing AJOVY to patients in Japan who could benefit from a preventive treatment.”

Last July, Teva reported positive findings from the exploratory endpoint analysis of the Phase IIIb FOCUS study that assessed fremanezumab as a preventive therapy for migraine in adults.

A clinically meaningful decrease was observed in the monthly average migraine days, with ≥50% response rates sustained over three months and significantly greater in subjects treated with fremanezumab.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena